Ldspharma

Facebook Linkedin
Menu

Nab-Paclid ® 100 mg Injection

Paclitaxel (albumin-bound 100mg)

NabPaclid-3-1080X1080
NabPaclid-2-1080X1080
NabPaclid-1-1080X1080

GENERIC NAME: Paclitaxel protein-bound particles for injectable suspension
(Albumin-bound)

THERAPEUTIC CLASS: Anti Neoplastic Agent

INDICATIONS & DOSAGE:

  • Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an
    anthracycline unless clinically contraindicated.
  • Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
  • Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.

STORAGE: Store below 30 °C. Protect from light.

PACK SIZE:  1×1’s

Download Brochure

DOSAGE & ADMINISTRATION:

  • Metastatic Breast Cancer (MBC): 260 mg/m2 intravenously over 30 minutes every 3 weeks.
  • Non-Small Cell Lung Cancer (NSCLC): 100 mg/m2 intravenously over

30 minutes on Days 1, 8, and 15 of each 21-day cycle; administer carboplatin on Day 1 of each 21-day cycle immediately after paclitaxel protein-bound particles for injectable
suspension.

  • Adenocarcinoma of the Pancreas: 125 mg/ m2m intravenously over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle; administer gemcitabine on Days 1, 8, and 15 of each 28-day cycle immediately after paclitaxel protein-bound particles